Stephen Machatha
Known title: Chief Development OfficerCIK: 0001836354
Associated companies
Transaction History
| ALDX | ▼ Sell | Open Market | 22,073 | $114K | 8/11/2025 | View on chart |
| ALDX | ▼ Sell | Open Market | 16,041 | $76K | 8/12/2024 | View on chart |
| ALDX | ▼ Sell | Open Market | 11,537 | $37K | 3/12/2024 | View on chart |
| ALDX | ▼ Sell | Open Market | 18,231 | $62K | 3/11/2024 | View on chart |
| ALDX | ▲ Buy | Grant | 185,605 | $0 | 7/15/2022 | View on chart |
| ALDX | ▲ Buy | Grant | 64,395 | $0 | 3/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Biotech Sector News Dominates; No Specific ALDX Updates
Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.
Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.